T Scardina1, L Labuszewski1, S M Pacheco2, W Adams3, P Schreckenberger4, S Johnson2. 1. 1Department of Pharmacy,Loyola University Medical Center,Maywood,Illinois,USA. 2. 2Edward Hines Jr. VA Hospital,Hines,Illinois,USA. 3. 4Loyola University Chicago,Chicago,Illinois,USA. 4. 5Department of Pathology,Loyola University Medical Center,Maywood,Illinois,USA.
Abstract
OBJECTIVE: Determine whether the NAP1 strain identified by polymerase chain reaction (PCR)-based stool assay is correlated with CDI severity and clinical outcomes. METHODS: Medical records of adult patients with positive stool Xpert® Clostridium difficile PCR assay for an initial episode of CDI between January 2012 and January 2013 at a tertiary care hospital in Chicago were reviewed. Two patients diagnosed with CDI caused by a non-NAP1 strain (positive Xpert® C. difficile assay but negative Xpert® C. difficile Epi assay) were included for each patient diagnosed with CDI caused by a NAP1 strain (positive Epi assay). Patient charts were reviewed for markers of severity, risk factors, treatment regimens, and outcomes. RESULTS: Of 494 stool specimens, 90 (18%) that were positive for C. difficile by PCR were positive for NAP1 strain. In total, 37 patients with CDI due to NAP1 were matched with 74 patients with CDI due to non-NAP1 strains. Multivariable model revealed individuals ≥65 years old were 3 times more likely to have NAP1 strain than individuals <65 (P=.02). Residents of a nursing home prior to hospitalization were 10 times more likely to have NAP1 strain than patients residing in their homes (P=.001). More NAP1 cases had a change in treatment from metronidazole to oral vancomycin plus intravenous metronidazole (P=.01). The severity of CDI, incidence of mortality and recurrent CDI were similar between groups. CONCLUSIONS: In a nonepidemic setting, NAP1 strains were more common in older patients and individuals admitted from nursing homes. Identification of NAP1 by PCR of stool specimens was associated in a change of therapy but did not predict worse outcomes. Reporting strain results may not be clinically useful in routine settings.
OBJECTIVE: Determine whether the NAP1 strain identified by polymerase chain reaction (PCR)-based stool assay is correlated with CDI severity and clinical outcomes. METHODS: Medical records of adult patients with positive stool Xpert® Clostridium difficile PCR assay for an initial episode of CDI between January 2012 and January 2013 at a tertiary care hospital in Chicago were reviewed. Two patients diagnosed with CDI caused by a non-NAP1 strain (positive Xpert® C. difficile assay but negative Xpert® C. difficile Epi assay) were included for each patient diagnosed with CDI caused by a NAP1 strain (positive Epi assay). Patient charts were reviewed for markers of severity, risk factors, treatment regimens, and outcomes. RESULTS: Of 494 stool specimens, 90 (18%) that were positive for C. difficile by PCR were positive for NAP1 strain. In total, 37 patients with CDI due to NAP1 were matched with 74 patients with CDI due to non-NAP1 strains. Multivariable model revealed individuals ≥65 years old were 3 times more likely to have NAP1 strain than individuals <65 (P=.02). Residents of a nursing home prior to hospitalization were 10 times more likely to have NAP1 strain than patients residing in their homes (P=.001). More NAP1 cases had a change in treatment from metronidazole to oral vancomycin plus intravenous metronidazole (P=.01). The severity of CDI, incidence of mortality and recurrent CDI were similar between groups. CONCLUSIONS: In a nonepidemic setting, NAP1 strains were more common in older patients and individuals admitted from nursing homes. Identification of NAP1 by PCR of stool specimens was associated in a change of therapy but did not predict worse outcomes. Reporting strain results may not be clinically useful in routine settings.
Authors: Kevin C Katz; George R Golding; Kelly Baekyung Choi; Linda Pelude; Kanchana R Amaratunga; Monica Taljaard; Stephanie Alexandre; Jun Chen Collet; Ian Davis; Tim Du; Gerald A Evans; Charles Frenette; Denise Gravel; Susy Hota; Pamela Kibsey; Joanne M Langley; Bonita E Lee; Camille Lemieux; Yves Longtin; Dominik Mertz; Lorraine Maze Dit Mieusement; Jessica Minion; Dorothy L Moore; Michael R Mulvey; Susan Richardson; Michelle Science; Andrew E Simor; Paula Stagg; Kathryn N Suh; Geoffrey Taylor; Alice Wong; Nisha Thampi Journal: CMAJ Date: 2018-06-25 Impact factor: 8.262
Authors: Andrew M Skinner; Laurica Petrella; Farida Siddiqui; Susan P Sambol; Christopher A Gulvik; Dale N Gerding; Curtis J Donskey; Stuart Johnson Journal: Emerg Infect Dis Date: 2020-02 Impact factor: 6.883